a new one was added in recent years-antimetabolites.
An antimetabolite may be defined as a compound bearing structural resemblance to a metabolite and capable of being attached to the enzyme for which the metabolite serves as the normal substrate. The enzymeantimetabolite complex, however, is incapable of undergoing the reactions of the enzyme-metabolite complex and, by interfering with the modification of the metabolite, a specific biochemical lesion is created.
The best example of truly effective antimetabolites is the sulfonamides, still among our most useful antibacterial agents. Sulfonamides are antimetabolites of p-aminobenzoic acid, which in turn is used by susceptible bacteria for the synthesis of coenzymes structurally related to pteroylglutamic (folic) acid.' The animal host cannot synthesize its own folic acid; most bacteria, on the other hand, cannot utilize preformed folic acid. Here, a clean-cut, qualitative metabolic difference between invading cells and the cells of the host has been exploited with considerable success.
After the discovery of the mode of action of the sulfa drugs which, incidentally, were found through screening synthetic dyes, rather than by the application of the principles discussed above, it seemed likely that the exploitation of biochemical differences between host and invading cells (whether bacteria, viruses, or neoplasms) would lead to the synthesis of a large number of potent drugs.
This approach, the design of antimetabolites, did lead to the synthesis of large numbers of organic compounds. However, while thousands of potential antimetabolites have been synthesized, the number of useful drugs among them has been disappointingly small. Certainly the most important medicinal agents to be introduced during the last twenty years, the antibiotics, did not originate in chemical laboratories but in such unlikely places as, for instance, the wounded knee of a little girl, a rotten cantaloupe, or in some of almost innumerable samples of soil. These antibiotic compounds, which have revolutionized the treatment of bacterial diseases, are the fruit of purely empirical screening, even though their therapeutic usefulness has in some cases been improved by chemical modification.
One of the reasons for the failure of so many antimetabolites may lie in the necessarily mechanical way in which they are being designed. Thus, as soon as the structure of a new metabolite is established, even when its biochemical role may not have been elucidated, dozens of potential "antimetabolites" are described in the literature within a matter of months. Generally, these are designed by the application of rather simple rules, atropine is a competitive antagonist of acetylcholine at post-ganglionic parasympathetic endings.'0 It can be seen that through the use of such considerations the term antimetabolite could be extended to include a large number of existing medicinal agents.
Unfortunately, information about substrate-enzyme interaction in terms of chemical mechanisms is very scarce and in most cases antimetabolites have to be designed without knowing which groups of the metabolite are functional. Even when a group known to be essential can be replaced by another, there can be no certainty that the change made will not be too great, in which case structural specificity is lost, or too small, in which case the analog may even be as functional as the compound which it mimics.
An example of a change of the latter type can be seen in selenopantethine,' the selenium analog of the sulfur compound, pantethine, which is the major component of coenzyme A (IV). The metabolic functions of this coenzyme are exerted through the formation of S-acyl intermediates,"' so that the chemical reactions of the whole complex molecule can be referred to its single atom IV.
of sulfur. Yet, when this sulfur was replaced by selenium, it was found that a microorganism requiring preformed pantethine grew just as well, on a mole for mole basis, on its selenium analog. Although it remains to be established that the organism, grown on the seleno-compound, contains a biologically functional seleno-coenzyme A, the probability of this is great. Another difficulty in working with antimetabolites relates to the assumption that drug and metabolite will behave differently only at the receptor site where inhibition is to take place, at which point antagonism will occur. At the same time, the tacit assumption is made that everywhere else in the body, in terms of metabolism, ability to be carried to the site of action, and toxicity unrelated to the site of action, metabolite and antimetabolite will behave in an identical fashion. This assumption, as would be expected, is hardly ever valid, since the replacement of chemical groups on a substrate by other groups usually alters the dissociation constant, lipid solubility, chemical reactivity, and paths of metabolic alteration of the molecule.
Changes in acid dissociation constant are particularly important, since the degree to which a drug is dissociated at physiological pH determines to what extent attachment to, or passage past, charged groups in biological tissues may occur. Since degree of dissociation stands in an inverse relationship to lipid solubility, it can be seen that as the pKa of a compound is altered, its ability to reach its site of action will be altered too.1 This is important, since anything that can be done to enable a functionally effective antimetabolite to reach its site on the biophase more efficiently than the metabolite will almost certainly make it a better antagonist.
Lipid solubility, as well as the degree of dissociation, is also important in enabling drugs to cross the blood-brain barrier."7 Failure to cross this "barrier" may increase the probability of resistant cells emerging within the brain' and greatly diminishes the value of drugs used in the treatment of diseases in which the central nervous system may be invaded by microorganisms or malignant cells.
If the fat solubility of a drug is too low, there are several methods by means of which it may be increased. The most widely used procedure is the introduction of long alkyl chains. This usually has the desired effect; however, the introduction of bulky groups changes the ability of drugs to attach themselves to receptor sites and may alter their mechanism of action completely. In a recent example of this it was found that pyridine-2-aldoxime methiodideTM (V), a reversing agent for acetylcholine esterase profoundly inhibited by "nerve gases," could not exert its effects in brain tissue, since the fat solubility of the aldoxime was too low. When its structure was modified in such a way that the methyl group of the aldoximederivative was replaced by the long-chain, lipid-solubilizing dodecyl group (VI), the new compound was very much more lipid soluble and able to affect structures uninfluenced by the parent compound. However, the introduction of the long alkyl chain gave the new compound depolarizing properties (which in view of its similarity to decamethonium (I) is not too surprising) and increased its toxicity.2t
Lipid solubility may also be increased by masking ionic groups, for instance by esterifying carboxyl or alkylating amino or hydroxy groups. However, since attachment to receptors is usually carried out by the groups now being altered, this procedure may result in loss of the desired activity.
It can be seen that in altering the fat solubility of a compound it is desirable to change its size, shape, and dissociation constants as little as possible. In some cases, this can be accomplished by replacement of oxygen by sulfur or even by selenium. In a recent study of several series of homologous heterocyclic oxygen, sulfur, and selenium compounds, it was found that this method of solubilization, which changes the configuration of the molecule very little, seems to be a generally effective one. ' The most important difficulty in designing antimetabolites, however, is not a chemical but a biochemical one. This is the frequent lack of qualitative metabolic differences between the cells of the host and the cells to be destroyed. This problem is particularly crucial in the field of cancer chemotherapy. Until now no enzymes have been found in malignant cells that are not present in normal cells.' While it has been reported recently that neoplasms may be profoundly deficient in some enzymes present in the host,' this finding would seem to be more useful for designing antimetabolites for freeing the tumor from the host than for doing the opposite! At best, it can be hoped that lack of catabolic enzymes may reduce preferentially the inactivation of a drug by tumor tissue.
Because of this lack of qualitative biochemical differences between normal and neoplastic cells, most carcinostatic antimetabolites are toxic to the cells of the host as well as to the cells of the tumors. Differential toxicity apparently is determined primarily by the greater rate at which the metabolite is depleted in the rapidly proliferating cells of the tumor as compared to the more slowly growing cells of the patient. This means that the therapeutic indices of these drugs tend to be quite low. When even a slight degree of drug resistance emerges, the dosage often cannot be raised enough to overcome it without causing intolerable toxicity to the host.
Since in designing antimetabolites it is important to decide just what one expects these compounds to do, it is convenient to subdivide them into several classes. These are:
1. Reversible antimetabolites. Here metabolite and antimetabolite compete for the same receptor sites. Since the inhibitor is bound comparatively loosely, it may be dislodged as the concentration of the metabolite is increased. The ratio of the two compounds at which inhibition takes place is a function of the relative firmness with which molecules of drug and molecules of normal substrate are held by the receptor once equilibrium has been established. If the concentration of both compounds is altered to the same extent, the degree of inhibition remains the same. The sulfonamides are representatives of the few effective drugs in this class.
2. Irreversible antimetabolites. Compounds which are bound so firmly that the metabolite cannot dislodge them at any concentration, may be subdivided into two groups: a. Endotoxic antintetabolites. These compounds are similar to the reversible antimetabolites discussed above in that those groups of the metabolite are modified through which attachment to the receptor takes place; however, with endotoxic antimetabolites very firm binding will result. For example, it has recently been shown that aminopterin and amethopterin are bound much more firmly to folic acid reductase than is the normal substrate, folic acid.' Presumably the amino group of the inhibitor is held more strongly by an acidic site than the analogous hydroxy group of the metabolite.2 It would seem likely that some essentially irreversible inhibitors of this type might become reversible as the pH of the system is changed.
b. Toxophoric antimetabolites. This name is proposed for antimetabolites carrying a highly reactive group (bis (B-chloroethyl)amino-, or diazomethyl groups, for instance) unrelated in structure and reactivity to any group of the normal metabolite. Since such substituents are rather bulky as well as reactive, it would seem desirable that they should not replace any groups responsible for attachment of the metabolite to the enzyme. Such replacement would be expected to result in loss of specificity of action. Rather, the toxic group should be adjacent to that area of the substrate at which attachment occurs, so that once enzyme-antimetabolite interaction has taken place, nearby sites of the enzyme could be attacked irreversibly with the formation of a covalent bond. Amino acid-mustards would be expected to exert their activity in this fashion.
Similarly, it might be hoped that compounds like 5-bis(,83-chloroethyl) aminouracil' (VII) or 8-bis(A-chloroethyl)amino-purines' (VIII) (or possibly their ribonucleosides or deoxyribonucleosides) might be incorporated into nucleic acids and then, through their "mustard" groups, perhaps The main problem with antimetabolites of this type would be expected to lie in the likelihood that they might undergo chemical reaction before having had time to reach the desired destination.
For a related discussion of irreversible antimetabolites the reader is referred to a recent paper by Baker.! 3. Aggregate antimetabolites. This type of compound was first postulated by Woolley, who suggested that two metabolites known to participate in a connected metabolic sequence could be converted into an antimetabolite by being united into a single molecule and proposed the above name.' Actually, it would seem unnecessary for two different metabolites to be united, but that it might suffice if two molecules of the same metabolite, or the same antimetabolite, were connected back to back, that is, linked in such a way that the chain between them would not interfere with attachment to receptor sites. Once an antimetabolite of this type would be attached, the probability of molecules of the metabolite dislodging it at both ends simultaneously would be rather low. If one end only were displaced, the probability of re-attachment of this end would be comparable to the probability of detachment of the other one. Succinoylcholine (IX), a dimer of acetylcholine, is one of the few examples of this type of compound; it is a widely used and very effective, neuromuscular blocking agent.' Recently some 8,8'-bispurinyl alkanes (X) have been synthesized' in the hope that such compounds might cause cross-linking between adjoining double helices of DNA and thus interfere with cell replication. It would now seem to be in order to review whether the antimetabolic approach has been or is likely to become a successful one. Although it seems likely that a research program based on the design of antimetabolites, in the long run will not produce more useful drugs than a program based on a more empirical basis, much is neglected by such a generalization. Certainly the likelihood of discovering valuable medicinal agents is particularly remote for workers synthesizing antimetabolites of compounds the functions of which are understood quite imperfectly or for workers dealing with anti-metabolites of compounds required by the host as much as by the invading cells.
However, the antimetabolite approach does have some very important advantages. While a weakly active, empirically designed compound has little or no scientific value, a weakly active, logically conceived antimetabolite may be a very valuable tool in gathering information about the metabolic functions of the compound with which it competes and about the receptor sites to which it is attached.
Thus, many antimetabolites do not simply compete with the compounds which they would be expected to mimic. For example, 5-fluorouracil turned out not to be a uracil antagonist in the body, but was reported as exerting its antileukemic activity by being converted to the deoxyribonucleotide and then interfering with the synthesis of thymidylic acid.8 Similarly, 6-azauracil is converted to the ribonucleotide and interferes with orotidylic acid decarboxylase,'2 while 6-mercaptopurine has also been reported to exert its carcinostatic action at the ribonucleotide level.' It can be seen that such compounds are very valuable in elucidating the metabolic paths of the substrates of which they are modifications. Furthermore, as a biochemical reaction is blocked we may see an accumulation of the product of the preceding metabolic step; this ultimately may lead to a nullification of the metabolic block. For instance, if in slow fast the reaction sequence: A -) B --C the step B -> C is blocked, we may be able to isolate the intermediate B, which otherwise might have remained undiscovered; thus, azaserine has been very helpful in elucidating some aspects of the biosynthesis of purines. '7 It would also seem that if the structures of metabolites are changed in such a fashion that their size remains essentially unaltered, but that the electron density of only one of the reactive groups is modified, much information about the reaction mechanisms of metabolite-enzyme interaction could be collected, at least if an isolated enzyme system were used. For example, a comparative study of the kinetics of ribonucleosidation of purines (XI) and triazolopyrimidines (XII) By measuring the dissociation constants of enzyme-substrate complexes of the enzyme with analogs in which the electrophilic character of only one group has been altered, we can gain knowledge about the acidity or basicity of the groups on the enzyme with which binding occurs. This would be particularly true if such measurements were carried out over a wide pH range. If, on the other hand, the electron density of the reactive groups is left unaltered, but the size of the molecule or the distance between the groups is modified, information can be collected about the shape of the sites where attachment is to occur. Such an approach has been used very successfully by Nachmansohn, Wilson, and their associates, in studying the receptor sites of acetylcholine esterase with the result that it became possible to design, on a rational basis, compounds for reversing inhibition of this enzyme. ' It would seem that at our present state of knowledge, in which we can discuss enzyme reactions mainly in terms of what substrate is attacked rather than in terms of the reaction mechanism of the attack, antimetabolites have their greatest value in explaining the mode of action of metabolites and in collecting information about receptor sites. The chance of finding useful drugs, at present, may be no higher than if any other chemotherapeutic approach were used, but it is intellectually a great deal more satisfying and much more productive of fundamental information upon which to build future advances.
Once enzymic reaction mechanisms and receptor sites would be understood in molecular terms rather than in terms of vague generalities, rational chemotherapy might become a reality. Antimetabolites would seem to be our most valuable tool for reaching this point.
